Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11

Area of Science:

• Epidemiology
• Immunology
• Public Health

Background:

• Human papillomavirus (HPV) vaccine types exhibit varying infectiousness and infectivity durations.
• This variation can lead to differences in population-level vaccine effectiveness, irrespective of identical vaccine efficacy.
• Understanding these differences is crucial for assessing the overall public health impact of HPV vaccination programs.

Purpose of the Study:

• To compare the type-specific effectiveness of vaccination against key HPV types (16, 18, 6, and 11).
• To evaluate the long-term population-level impact of HPV vaccination strategies.
• To inform the design and interpretation of post-vaccination surveillance studies.

Main Methods:

• Developed an individual-based stochastic model simulating HPV transmission across 18 HPV types.
• Stratified the population model by age, gender, and sexual activity levels.
• Calibrated model parameters using sexual behavior data and type-specific HPV prevalence data.

Main Results:

• Under base case assumptions (70% coverage, 99% efficacy, 20-year protection), HPV-16, HPV-18, and HPV-6/11 prevalence reductions were predicted at 61%, 92%, and 100% respectively after 50 years.
• Significant differences in type-specific vaccine effectiveness emerged and increased over time.
• Effectiveness differences diminished with improved vaccine efficacy characteristics.

Conclusions:

• Population-level impact of HPV vaccination differs by type, with HPV-16 (most oncogenic) demonstrating the lowest effectiveness, even with equal vaccine efficacy.
• Type-specific effectiveness differences are influenced by duration of protection and vaccine efficacy.
• Findings necessitate careful consideration in designing and interpreting post-vaccination surveillance studies for accurate public health assessments.